1404115-38-3

Basic information

• Product Name: (2-bromo-3,6-difluorophenyl)methanol
• Synonyms: (2-bromo-3,6-difluorophenyl)methanol
• CAS NO: 1404115-38-3
• Molecular Weight: 223.017
• Mol File: 1404115-38-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2-bromo-3,6-difluorophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-bromo-3,6-difluorophenyl)methanol(1404115-38-3)
• EPA Substance Registry System: (2-bromo-3,6-difluorophenyl)methanol(1404115-38-3)

Safety Data

• Hazardous Substances Data: 1404115-38-3(Hazardous Substances Data)

Usage

General Description

(2-bromo-3,6-difluorophenyl)methanol is a chemical compound with the molecular formula C7H5BrF2O. It is an organic compound that contains a bromine atom, two fluorine atoms, and a phenyl ring with a hydroxyl group attached to it. (2-bromo-3,6-difluorophenyl)methanol is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also used in the production of various organic compounds and materials. Additionally, (2-bromo-3,6-difluorophenyl)methanol has potential applications in the field of medicinal chemistry and drug discovery due to its unique structural features and properties. However, it is important to handle this chemical with care as it may pose health and environmental risks if not properly managed.

Upstream product

• 934987-26-5 2-bromo-3,6-difluoro-benzaldehyde 

Downstream Products

• 1404115-42-9 C₁₃H₁₆BrF₂NO₂ 
• 1380021-30-6 C₈H₈BrF₂N 
• 1256482-82-2 C₈H₄BrF₂N 

Relevant articles and documents

HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models.

Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship

The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.